MichelleL.MellionMD

Neurophysiology

Assistant Professor, Neurology, Brown University Program in Medicine

Dr. Mellion is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
2 Dudley St
Ste 555
Providence, RI 02905
Phone+1 401-444-3032

Fax+1 401-444-3205

Brown UniversityFellowship, Clinical Neurophysiology, 2005 - 2006
Brown UniversityResidency, Neurology, 2002 - 2005
Brown UniversityInternship, Internal Medicine, 2001 - 2002
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2001

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013

PubMed

391 citations
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-bli...
James F. Howard, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn
The Lancet. Neurology. 2017-12-01
17 citations
Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement
Michelle Mellion, Lucienne Ronco, Cécile Berends, Lisa Pagan, Sander Brooks
British Journal of Clinical Pharmacology. 2021-05-14
12 citations
Experimental Alcohol-Related Peripheral Neuropathy: Role of Insulin/IGF Resistance
Van Anh Nguyen, Tran Le, Ming Tong, Michelle Mellion, James M. Gilchrist
Nutrients. 2012-08-17

PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical DevelopmentApril 5th, 2022
Phase 1 Results Support Losmapimod as FSHD TreatmentMarch 26th, 2020
Fulcrum Therapeutics Announces Phase 1 Clinical Trial ResultsOctober 4th, 2019